Lundbeck and EVERSANA Forge Partnership to Enhance AI-driven Commercial Practices

In a significant move, global pharmaceutical leader Lundbeck has announced a strategic alliance with EVERSANA, a frontrunner in commercial services tailored for the life sciences sector. This partnership is designed to leverage AI technology to streamline and enhance commercialization processes within Lundbeck's U.S. operations, focusing on the promotion of brain health initiatives.

Understanding the Partnership

Lundbeck, which has carved its niche in the biopharmaceutical arena with an emphasis on brain health, sees this collaboration as a vital step toward realizing its Focused Innovator strategy. Central to this partnership is the deployment of EVERSANA’s AI Agency platform, which provides advanced commercialization capabilities. This initiative aims to create a robust framework for efficient strategy development, content creation, and comprehensive engagement across multiple channels.

Tom Gibbs, EVP and President of Lundbeck U.S., highlighted the importance of integrating human expertise with artificial intelligence. This new operational model is expected to strengthen decision-making and implementation processes, ultimately delivering enhanced value to customers and patients while adhering to the high compliance and quality standards essential in the pharmaceutical industry.

Objectives of the Collaboration

The primary aim of this partnership is to scale AI-enabled capabilities throughout various commercial functions, including marketing, market access, medical communications, and media operations. By broadening the application of AI, Lundbeck and EVERSANA intend to not only expedite strategic planning and execution but also enhance the overall quality of their output.

Lundbeck's trailblazing efforts in this domain have already seen the effective deployment of AI-driven workflows in initial commercial activities. The partnership promises to build on these advancements, ensuring that rigorous medical and regulatory review processes remain intact while enabling faster and more efficient operations.

Mark Thierer, CEO of EVERSANA, stated that the future of successful commercialization lies in blending human expertise with AI execution. By joining forces, both companies aim to set a new standard in how the life sciences industry approaches product commercialization.

Innovative AI Integration

Launched in 2025, EVERSANA’s AI Agency is a comprehensive platform specifically designed for life sciences commercialization. Developed alongside Google Cloud, this platform integrates agentic AI, advanced automation, and human insight to bolster the development of strategic frameworks and facilitate omnichannel engagement. Importantly, it aligns with the compliance and governance standards mandatory in the pharmaceutical landscape.

What distinguishes this collaboration is the focus on adopting an AI-powered operating model tailored to the unique needs of life sciences. Faruk Capan, Chief Innovation Officer at EVERSANA, emphasized that the aim is to equip commercial teams with the tools to expedite execution without sacrificing the quality that healthcare demands.

Future Prospects

The strategic alliance is a testament to both companies' commitment to innovating the commercialization landscape. By merging advanced technological capabilities with profound industry knowledge, Lundbeck and EVERSANA aspire to reshape the methodologies employed in pharmaceutical commercialization, ensuring a brighter future for patients with neurological and psychiatric conditions.

Conclusion

Lundbeck and EVERSANA’s partnership marks a pivotal moment in the healthcare industry. The integration of AI into their commercialization strategies not only fosters a culture of innovation but also underscores the importance of producing effective solutions that resonate with healthcare providers and patients alike. This collaboration exemplifies how technology can redefine industry standards while maintaining the utmost integrity and commitment to improving brain health globally.